Release of soluble vascular endothelial growth factor receptor-1 (sFlt-1) during coronary artery bypass surgery

doi:10.1186/1749-8090-2-38

Journal of Cardiothoracic Surgery

Volume 2

Viewing options:

Abstract
Full text
PDF (330KB)

Associated material:

Related literature:

Articles citing this article
on BioMed Central
on Google Scholar
on ISI Web of Science
on PubMed Central
Other articles by authors
on Google Scholar

Denizot Y
Leguyader A
Cornu E
Laskar M
Orsel I
Vincent C
Nathan N

on PubMed

Denizot Y
Leguyader A
Cornu E
Laskar M
Orsel I
Vincent C
Nathan N
Related articles/pages
on Google

on Google Scholar

on PubMed

Tools:

Post to:

Research article

Release of soluble vascular endothelial growth factor receptor-1 (sFlt-1) during coronary artery bypass surgery

Yves Denizot¹ , Alexandre Leguyader² , Elisabeth Cornu² , Marc Laskar² , Isabelle Orsel³ , Christelle Vincent¹ and Nathalie Nathan³

¹UMR CNRS 6101, Centre National de la Recherche Scientifique, Université de Limoges, France

²Service de Chirurgie Thoracique et Cardiovasculaire, CHU Dupuytren, Limoges, France

³Service d'Anesthésie Réanimation Chirurgicale, CHU Dupuytren, Limoges, France

author email corresponding author email

Journal of Cardiothoracic Surgery 2007, 2:38doi:10.1186/1749-8090-2-38


Published:	21 September 2007

Abstract

Background

This study was conducted to follow plasma concentrations of sFlt-1 and sKDR, two soluble forms of the vascular endothelial growth factor (VEGF) receptor in patients undergoing coronary artery bypass graft (CABG) surgery with extracorporeal circulation (ECC).

Methods

Plasma samples were obtained before, during and after surgery in 15 patients scheduled to undergo CABG. Levels of sFlt-1 and KDR levels were investigated using specific ELISA.

Results

A 75-fold increase of sFlt-1 was found during cardiac surgery, sFlt-1 levels returning to pre-operative values at the 6^thpost-operative hour. In contrast sKDR levels did not change during surgery. The ECC-derived sFlt-1 was functional as judge by its inhibitory effect on the VEGF mitogenic response in human umbilical vein endothelial cells (HUVECs). Kinetic experiments revealed sFlt-1 release immediately after the beginning of ECC suggesting a proteolysis of its membrane form (mFlt-1) rather than an elevated transcription/translation process. Flow cytometry analysis highlighted no effect of ECC on the shedding of mFlt-1 on platelets and leukocytes suggesting vascular endothelial cell as a putative cell source for the ECC-derived sFlt-1.

Conclusion

sFlt-1 is released during CABG with ECC. It might be suggested that sFlt-1 production, by neutralizing VEGF and/or by inactivating membrane-bound Flt-1 and KDR receptors, might play a role in the occurrence of post-CABG complication.